期刊文献+

柱切换高效液相色谱法测定人血浆中替米沙坦浓度 被引量:9

Column-switching HPLC determination of telmisartan in human plasma
暂未订购
导出
摘要 目的:建立柱切换高效液相色谱(HPLC)法直接进样测定人血浆中替米沙坦浓度。方法:血浆样品直接进样,经限进填料(RAM)预柱用甲醇-水(10:90)在线净化和富集,然后洗脱切入 C_(18)分析柱用甲醇-水(63:37)进行分离,荧光检测λ_(ex)302nm/λ_(em)365nm。结果:标准曲线线性范围10~2000μg·L^(-1)(r=0.9995);回收率为95.4%~97.7%(n=5);日内 RSD 为0.2%~2.6%(n=5),日间 RSD 为2.1%~4.1%(n=5);最低检测浓度为0.51μg·L^(-1)。结论:本法简便、可靠,适用于测定人血浆中替米沙坦浓度及其药动学的研究。 Objective:To establish a column -switching high performance liquid chromatographic (HPLC) method for the determination of telmisartan in human plasma by direct injection. Methods:The plasma samples injected directly onto the pre -column packing with restricted -access materials(RAM) were on -line washed with methanol -water( 10: 90),and the component were eluted onto analytical column to separate with methanol- water(63: 37). The flow rate was 1.0 mL · min^-1 with fluorescence detection set at λex 302 nm and λem 365 nm. Results:The calibration linear range for telmisartan in plasma was 10 - 2000 μg · L^- 1 with correlation coefficient of 0. 9995 while the limit of quantification was 0.51 μg · L^-1. The recoveries of method were 95.4% -97.7% ( n =5 ). The RSD of intra - day and inter - day were 0.2% -2.6% and 2.1% -4. 1% ( n =5 ) ,respectively. Conclnsions:This method is simple and reliable for the determination of telmisartan in human plasma and its pharmacokinetic study.
出处 《药物分析杂志》 CAS CSCD 北大核心 2006年第8期1071-1073,共3页 Chinese Journal of Pharmaceutical Analysis
关键词 替米沙坦 高效液相色谱 限进填料 柱切换 telmisartan HPLC restricted - access media column - switching
  • 相关文献

参考文献11

二级参考文献30

  • 1Sharpe M,Jarvis B,Goa KL. Telmisartan:a review of its use in hypertension. Drugs ,2001,61 (10): 1501.
  • 2Torrealday N,Gonza]ez L,Alonso RM, et al. Experimental design approach for the optimization of a HPLC - fluorimetric method for the quantitation of the angiotensin Ⅱ receptor antagonist telmisartan in urine. J Pharm Biomed Anal ,2003,32:847.
  • 3Stangier J, Su CAPF, Brickl R, et al. Pharmacokinetics of single -dose telmisartan 120 mg given during ang between hemodiaysis in subjects with severe renal insufficiency:comparison with healthy volunteers. J Clin Pharmacol ,2000,40(12):1365.
  • 4Stangier J,Schmid J,Turck D, et al. Absorption,metabolism,and excretion of intravenously and orally administered [ 14C ] telmisartan inhealthy volunteers. J Clin Pharmacol ,2000,40(12):1312.
  • 5Stangier J,Su CAPF, Fraunhofer A, et al. Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. J Clin Pharmacol ,2000,40(12):1338.
  • 6Stungier J, Su CAPF, Schondorfer G, et al. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment comparison with healthy volunteers. J Clin Pharmacol ,2000,40(12): 1355.
  • 7Wang D J,J Chromatogr,1988年,431卷,418页
  • 8马骏,色谱,1997年,15卷,33页
  • 9朱彭龄,现代液相色谱,1988年,73页
  • 10Stangier J, Schmid J, Turck D,et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C] telmisartan in healthy volunteers. J Clin Pharmacol, 2000,40 : 1312.

共引文献33

同被引文献126

引证文献9

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部